期刊
CLINICAL & TRANSLATIONAL ONCOLOGY
卷 25, 期 9, 页码 2679-2691出版社
SPRINGER INT PUBL AG
DOI: 10.1007/s12094-023-03216-3
关键词
Small-cell lung cancer; Clinical practice guidelines; Diagnosis; Treatment; Follow-up
类别
Small-cell lung cancer (SCLC) accounts for about 15% of lung cancers and is highly aggressive. Surgical resection followed by adjuvant therapy is curative for limited-stage SCLC, but only a minority of patients are eligible for surgery. Concurrent chemo-radiotherapy is the standard treatment for inoperable limited-stage SCLC, while combination chemotherapy with programmed death-ligand 1 inhibitors has become the new front-line standard for extensive-stage SCLC. Advances in understanding SCLC biology and new treatment approaches offer potential improvements in patient care.
Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of lung cancers. Only one-third of patients are diagnosed at limited-stage (LS). Surgical resection can be curative in early stages, followed by platinum-etoposide adjuvant therapy, although only a minority of patients with SCLC qualify for surgery. Concurrent chemo-radiotherapy is the standard of care for LS-SCLC that is not surgically resectable, followed by prophylactic cranial irradiation (PCI) for patients without progression. For extensive-stage (ES)-SCLC, a combination of platinum and etoposide has historically been a mainstay of treatment. Recently, the efficacy of programmed death-ligand 1 inhibitors combined with chemotherapy has become the new front-line standard of care for ES-SCLC. Emerging knowledge regarding SCLC biology, including genomic characterization and molecular subtyping, and new treatment approaches will potentially lead to advances in SCLC patient care.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据